Byondis' antibody-drug conjugate treatment was assessed in a phase 3 trial dubbed TULIP.
Byondis' efforts to get an antibody-drug conjugate (ADC) treatment for HER-2 positive metastatic breast cancerHER-2 positive metastatic breast cancer approved have been pruned by the FDA.
Now, the agency has rejected the drug in a complete response letter, saying that further unspecified information is needed, according to the biotech's Monday release. Byondis said the request would require time and resources “that extend beyond the current evaluation period,” according to a company release.
The biotech expressed disappointment but plans to continue seeking approval of the lead asset in the EU and the U.K.
"We continue to believe that SYD985 can present a meaningful treatment option for patients living with HER2-positive metastatic breast cancerHER2-positive metastatic breast cancer," Byondis CEO Marco Timmers, Ph.D., said in a May 15 release. "We appreciate the FDA's guidance and support and will carefully evaluate the complete response letter and consider potential next steps."
SYD985 was assessed in a multicenter, open-label, randomized phase 3 trial dubbed TULIP. The study showed a statistically significant improvement over a physician's choice of treatment among 436 patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancerHER2-positive unresectable locally advanced or metastatic breast cancer, according to Byondis.
The asset—which received fast-track designation from the FDA in 2018—contains the monoclonal antibody Herceptin and an investigational cleavable linker drug, which can help boost the success of ADC therapies by making tumor cells selectively release the toxin in the therapy.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.